On Thursday, Nexalin Technology Inc. (NASDAQ: NXL) saw its stock rise 6.7%. The increase followed the announcement of its new AI-designed virtual clinic platform, NeuroCare. This platform was developed in collaboration with the University of California, San Diego.
NeuroCare marks the first phase of Nexalin’s digital health ecosystem. It aims to improve patient access, lower costs, and provide long-term care for brain health conditions. The virtual clinic pairs with Nexalin’s Gen-3 HALO headset, which uses Deep Intracranial Frequency Stimulation (DIFS) technology.
Through the platform, patients can receive neurostimulation treatment for conditions like Alzheimer’s, dementia, depression, anxiety, traumatic brain injury, and PTSD. Importantly, treatments can be done at home. The system also includes remote monitoring and operates on a subscription-based model.
Mark White, CEO of Nexalin, highlighted the platform’s potential. “Today we begin a new chapter in how brain-health therapy is delivered,” he said. “By launching our Gen-3 HALO neurostimulation system with the NeuroCare AI-designed virtual clinic platform, in partnership with UCSD, we remove the mental health stigma, eliminate access barriers to treatment, and lower the cost for patients and physicians alike.”
The platform is designed to address traditional challenges in mental health care. It eliminates waiting rooms and offers private, home-based treatment. Physicians can monitor and manage treatments in real time using advanced tools.
Nexalin believes NeuroCare will drive scalable, data-driven revenue growth globally. The company plans to move beyond device sales and focus on recurring revenue streams. This launch represents a significant step in transforming mental health care delivery.
The post Nexalin Technology Shares Surge with Launch of AI-Powered Virtual Clinic appeared first on PRISM MarketView.
